Currently, kidney transplantation is the best treatment option for patients with chronic kidney disease in the terminal stage. However, despite the progress achieved with the advent of powerful new immunosuppressive drugs, able to reduce the incidence of graft rejection, the need for their chronic use is associated with significant side effects such as increased risk of opportunistic infectious diseases and cancer. Thus, we must seek new treatment alternatives that can minimize the side effects of immunosuppressive drugs or even replace them in the future.It is known that the mesenchymal stem cells (MSC) exhibit an important control of the immune response which makes them strategic candidates for cell therapy in order to prevent acute and chronic rejection in kidney transplants.The main objective of this proposal is to evaluate the use of renal perfusion with MSC as an alternative route of infusion and evaluate the immunosuppressive activity of these cells.Specifically, we will analyze the effects of the MSC and of the ways in relation to the functional and morphological parameters of the graft as well as possible immunomodulatory mechanisms induced by this treatment strategy. The lymphoid organs will be further studied to evaluate and confirm the migratory pattern and "engrafment" of cells as well as its impact on non-proliferation or induce regulatory T cells (Tregs).
News published in Agência FAPESP Newsletter about the scholarship: